DK473987D0 - PROCEDURE FOR CONTINUOUS PRODUCTION OF A DESIRED HETEROLOGICAL PROTEIN IN AN EU ECARYOTIC CELL, VECTOR APPLYING THAT ABILITY AND CELLS TRANSFORMED WITH THE VECTOR - Google Patents

PROCEDURE FOR CONTINUOUS PRODUCTION OF A DESIRED HETEROLOGICAL PROTEIN IN AN EU ECARYOTIC CELL, VECTOR APPLYING THAT ABILITY AND CELLS TRANSFORMED WITH THE VECTOR

Info

Publication number
DK473987D0
DK473987D0 DK473987A DK473987A DK473987D0 DK 473987 D0 DK473987 D0 DK 473987D0 DK 473987 A DK473987 A DK 473987A DK 473987 A DK473987 A DK 473987A DK 473987 D0 DK473987 D0 DK 473987D0
Authority
DK
Denmark
Prior art keywords
vector
ecaryotic
ability
procedure
cell
Prior art date
Application number
DK473987A
Other languages
Danish (da)
Other versions
DK175363B1 (en
DK473987A (en
Inventor
Cornelia Maxine Gorman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DK473987D0 publication Critical patent/DK473987D0/en
Publication of DK473987A publication Critical patent/DK473987A/en
Application granted granted Critical
Publication of DK175363B1 publication Critical patent/DK175363B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
DK473987A 1986-09-12 1987-09-11 Process for Continuous Production of a Desired Heterologous Protein in a Eukaryotic Host Cell, Vector Adding That Ability, and Cells Transformed with the Vector DK175363B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90718586A 1986-09-12 1986-09-12
US90718586 1986-09-12
US7167487A 1987-07-09 1987-07-09
US7167487 1987-07-09

Publications (3)

Publication Number Publication Date
DK473987D0 true DK473987D0 (en) 1987-09-11
DK473987A DK473987A (en) 1988-03-13
DK175363B1 DK175363B1 (en) 2004-09-13

Family

ID=26752513

Family Applications (1)

Application Number Title Priority Date Filing Date
DK473987A DK175363B1 (en) 1986-09-12 1987-09-11 Process for Continuous Production of a Desired Heterologous Protein in a Eukaryotic Host Cell, Vector Adding That Ability, and Cells Transformed with the Vector

Country Status (9)

Country Link
EP (1) EP0260148A3 (en)
JP (3) JP2888518B2 (en)
AU (1) AU613316B2 (en)
DE (1) DE3730599A1 (en)
DK (1) DK175363B1 (en)
FR (1) FR2603899B1 (en)
GB (1) GB2197321B (en)
IE (1) IE872455L (en)
NZ (1) NZ221790A (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
DE3545126A1 (en) * 1985-12-19 1987-06-25 Boehringer Mannheim Gmbh METHOD FOR IMPROVING THE EXPRESSION OF EUKARYON PROTEIN
AU613876B2 (en) * 1986-10-01 1991-08-15 Merck & Co., Inc. Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1990002569A1 (en) * 1988-09-06 1990-03-22 International Genetic Engineering, Inc. Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
DE68929419T2 (en) * 1988-12-13 2003-04-03 Harvard College Prototype FeLV isolates for use as a disease pattern or vaccine
JPH02261386A (en) * 1989-03-31 1990-10-24 Kyowa Hakko Kogyo Co Ltd Recombinant vector
JP2857684B2 (en) * 1989-05-04 1999-02-17 ジェネンテク，インコーポレイテッド Methods and compositions for the isolation of human relaxin
CA2018676C (en) * 1989-06-20 2003-05-06 Christie A. Kelton Novel heteropolymeric protein production methods
SE8903865D0 (en) * 1989-11-17 1989-11-17 Kabigen Ab EXPRESSION OF HETEROLOGOUS PROTEINS USING EUKARYOTIC CELLS
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
GB9027917D0 (en) * 1990-12-21 1991-02-13 Ici Plc Expression systems
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
DE69433925T2 (en) * 1993-06-10 2005-07-28 Bayer Corp. Mammalian vectors and cell lines with increased productivity
GB9408573D0 (en) * 1994-04-29 1994-06-22 Gatsby Charitable Foundation Identification, production and use of saponin gylcosyl hydrolases
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
EP0909277B2 (en) 1996-06-07 2008-12-24 Poniard Pharmaceuticals, Inc. Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
WO1998031394A2 (en) 1997-01-22 1998-07-23 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment
US5854021A (en) * 1997-02-28 1998-12-29 Bayer Corporation Enhance protein production method
JP2002517180A (en) 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン Novel vectors and genes exhibiting increased expression
CA2331789C (en) 1998-07-13 2013-09-10 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6051401A (en) * 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
FR2823222B1 (en) 2001-04-06 2004-02-06 Merial Sas VACCINE AGAINST NILE FEVER VIRUS
AU2003275127A1 (en) 2002-09-19 2004-04-08 Merial Limited P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
WO2004039958A2 (en) 2002-10-29 2004-05-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use
MXPA05008756A (en) 2003-02-19 2005-10-05 Merial Ltd Vaccination or immunization using a prime-boost regimen against brsv, bhv-1, bvdv, bpi-3.
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
BRPI0415296A (en) * 2003-10-16 2006-12-26 Claude Negrier cdna modified for high expression levels of factor viii and its derivatives
WO2006115843A2 (en) 2005-04-25 2006-11-02 Merial Limited Nipah virus vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US7455844B2 (en) 2006-03-29 2008-11-25 Merial Limited Vaccine against streptococci
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
CA2684923C (en) 2007-05-02 2015-01-06 Merial Limited Dna plasmids having improved expression and stability
EP2283035B1 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
CN102271704A (en) 2008-11-28 2011-12-07 梅里亚有限公司 Recombinant avian influenza vaccine and uses thereof
EP2414386B1 (en) 2009-04-03 2016-01-27 Merial Limited Newcastle disease virus vectored avian vaccines
SI2432884T1 (en) 2009-05-22 2016-11-30 Merial, Inc. Antibiotic-free plasmid
BR112012023852B1 (en) 2010-03-12 2020-11-10 Biolex Therapeutics recombinant blue tongue virus vaccines and their uses
BR112013007486B1 (en) 2010-08-31 2020-01-28 Merial Ltd composition, recombinant ndv vector and use of said composition
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
LT2734230T (en) 2011-07-20 2019-03-25 Merial Limited Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
NZ700470A (en) 2012-03-20 2016-04-29 Merial Inc Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
ES2664069T3 (en) 2012-06-13 2018-04-18 Merial, Inc. BTV and AHSV vaccines of rearranged genome
RU2500817C1 (en) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") RECOMBINANT PLASMID DNA pBK415 CODING POLYPEPTIDE OF RECOMBINANT TISSULAR ACTIVATOR OF PLASMINOGEN OF HUMAN BEING, CELL LINE Cricetulus griseus CHO 1F8-PRODUCER OF RECOMBINANT TISSULAR ACTIVATOR OF PLASMINOGEN OF HUMAN BEING, AND METHOD FOR OBTAINING AND SEPARATION OF POLYPEPTIDE HAVING ACTIVITY OF TISSULAR ACTIVATOR OF PLASMINOGEN
US10010594B2 (en) 2014-02-11 2018-07-03 University Of Miami Methods and compositions for transgene expression in a herpesvirus vector system
EP3215188A1 (en) 2014-11-03 2017-09-13 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
AU2016282772B2 (en) 2015-06-23 2019-09-05 Boehringer Ingelheim Animal Health USA Inc. PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof
WO2017031120A1 (en) 2015-08-20 2017-02-23 Merial, Inc. Fcv recombinant vaccines and uses thereof
AU2016332037B2 (en) 2015-09-29 2019-06-27 Boehringer Ingelheim Animal Health USA Inc. Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof
EP3380119B1 (en) 2015-11-23 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Fmdv and e2 fusion proteins and uses thereof
TWI760322B (en) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 Recombinant adenovirus vectored fmdv vaccines and uses thereof
JP7287611B2 (en) * 2018-02-07 2023-06-06 学校法人日本医科大学 Improved adeno-associated virus vector

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI86885C (en) * 1984-04-20 1992-10-26 Genentech Inc Method for Preparation of Human Recombinant Factor VIII and Nucleic Acid Sequences and Vectors Used thereto
DE3431140A1 (en) * 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg ENHANCER FOR EUKARYOTIC EXPRESSION SYSTEMS
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin

Also Published As

Publication number Publication date
EP0260148A3 (en) 1989-06-07
NZ221790A (en) 1990-07-26
GB8721424D0 (en) 1987-10-21
GB2197321B (en) 1990-10-03
JPH09103296A (en) 1997-04-22
IE872455L (en) 1988-03-12
AU7831787A (en) 1988-05-19
EP0260148A2 (en) 1988-03-16
JP3148121B2 (en) 2001-03-19
JP2888518B2 (en) 1999-05-10
DE3730599A1 (en) 1988-07-07
JPS63152986A (en) 1988-06-25
FR2603899B1 (en) 1990-07-13
FR2603899A1 (en) 1988-03-18
DK175363B1 (en) 2004-09-13
JP2000308497A (en) 2000-11-07
AU613316B2 (en) 1991-08-01
GB2197321A (en) 1988-05-18
DK473987A (en) 1988-03-13

Similar Documents

Publication Publication Date Title
DK473987D0 (en) PROCEDURE FOR CONTINUOUS PRODUCTION OF A DESIRED HETEROLOGICAL PROTEIN IN AN EU ECARYOTIC CELL, VECTOR APPLYING THAT ABILITY AND CELLS TRANSFORMED WITH THE VECTOR
DK638389D0 (en) TRANSFORMING GROWTH FACTOR-BETA2 AND PRECAUTIONS THEREOF, PROCEDURES FOR THEIR PREPARATION, THE NUCLEOTIDE SEQUENCE THAT CODES THEREOF, AND ECHARIOTIC CELLS AND CELL LINES CONTAINING THIS
DK155834C (en) PROCEDURE FOR MANUFACTURING POLYANILINES AND THEIR USE AS ACTIVE ELECTRODEMATIC MATERIAL IN ELECTROCHEMICAL GENERATORS
DK189090A (en) PROTEINS THAT PROMOTE IMMUNOLOGICAL EFFECT CELL ACTIVATION AND CHEMISTRY
EP0369666A3 (en) Solar cell
DK209781A (en) ELECTRODES PROCEDURE FOR THEIR PREPARATION AND THEIR USE IN ELECTROCHEMICAL CELLS
ZA864525B (en) Vector for expression of interferon-ypsilon in mammalian cells,method for using it and product obtained
GB8829948D0 (en) Electrochemical cells
AU581264B2 (en) Electrode for electrochemical processes,method for preparing the same and use thereof in electrolysis cells
GB2219430B (en) Electrochemical cell
GB8503455D0 (en) Performing micro-operations on cells
DK387186D0 (en) PROCEDURE FOR THE MANUFACTURING OF AN ELECTRODE AND ITS APPLICATION IN ELECTROCHEMICAL PROCESSES
GB2225153B (en) Electrochemical cell
DK169389D0 (en) APPARATUS AND PROCEDURE FOR DETERMINING THE FUNCTION OF CELLS
GB2226442B (en) Electrochemical cell
DK85084D0 (en) IMMUNGLOBULIN-PRODUCING HYBRID CELL LINES, THEIR USE AND PROCEDURE FOR THEIR PREPARATION
GB2226181B (en) Electrochemical cell
DE3686844D1 (en) NON-AQUEOUS LIQUID ELECTROLYTE FOR ELECTROLYT CAPACITORS, AND CAPACITORS USING THEM.
DK282686A (en) PROCEDURE AND APPARATUS FOR FINDING THE LOCKING STATE IN AN EXTENSIVE TURISTOR
GB2216337B (en) Solar cell and fabrication method thereof
NO872952D0 (en) CATHOD FOR USE IN HYDROGEN DEVELOPING ELECTROCHEMICAL PROCESSES, AND PROCEDURE FOR THE PREPARATION OF THE CATHOD.
DK182687A (en) METHOD AND APPARATUS FOR MANUFACTURING THE GALVANIC BATTERY SEPARATOR
DK108790A (en) PROCEDURE FOR MULTIPLE OXIDATION OF STEROIDS AND GENETICALLY TREATED CELLS FOR USING THE PROCEDURE
NO171566C (en) ANODE FOR USE IN AN ELECTROLYCLE CELL AND PROCEDURE FOR MANUFACTURING THE ANOD
GB2225667B (en) Electrochemical cell

Legal Events

Date Code Title Description
PUP Patent expired